Use of serum levels of cytokine TGF &bgr;1 in detection of Hepatocellular carcinoma in patients with chronic liver disease

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Mehmedovic
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors A. Mehmedovic1, B. Prnjavorac2, Z. Vukobrat- Bijedić1
  • 1Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina, /
  • 2Faculty of pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina, /

Abstract

The hepatocellular carcinoma (HCC) is one of the most common malignant tumors and carries a poor survival rate. Increased understanding of cancer biology and technological advances have enabled identification of a multitude of pathological, genetic, and molecular events that drive hepatocarcinogenesis leading to discovery of numerous potential biomarkers in this disease. The transforming growth factor-beta (TGF-�) cytokine and its isoforms initiate a signaling cascade which is closely linked to liver fibrosis, cirrhosis and subsequent progression to HCC.